

03 March 2026

## **Ophthalmology Use of Kenalog (Triamcinolone)**

**I am submitting a request under the Freedom of Information Act 2000.**

**Please provide the following information relating specifically to the use of Kenalog (triamcinolone) within your Ophthalmology department:**

**1. The number of Kenalog administrations carried out in Ophthalmology for each of the last three financial years.**

- There is likely to be on average 12 administrations per year however to be precise this would require a manual chart review of all patients currently attending Uveitis, Macular and the Vitreo Retinal service within Ophthalmology, this would require more than 18 hours given to respond which would exceed the costs limit specified in the FOI act.

We estimate that compliance with this element of the request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

**2. A breakdown of the clinical indications recorded for Kenalog use in Ophthalmology (e.g., uveitis, macular oedema, post-operative inflammation), if available.**

- Uveitis, post operative macular oedema, vitreoretinal to stain vitreous, however the service is now using intracinal which is a licensed device for this purpose.

**3. Any local guidelines, protocols, or clinical policies governing the use of Kenalog in Ophthalmology.**

- No local guidelines or protocols as the device is used "off label" for Ophthalmology

**4. Any recorded adverse events, Datix reports, or safety concerns relating to Kenalog use in Ophthalmology during the same period.**

- No Datix reports or safety concerns noted within the same time period.

**03 March 2026**

**5. The number of vials issued by pharmacy to Ophthalmology for Kenalog in each of the last three financial years, if held.**

- Not held.

**6. Whether Kenalog (triamcinolone) is listed on the Trust's formulary for Ophthalmology, and if so, any restrictions or criteria for its use.**

- Not listed as used off label.

**7. As Kenalog has been withdrawn from the UK market, please provide any recorded information, internal communications, policies, or decisions relating to:**

- **whether the Ophthalmology department is continuing to use existing stock,**
  - Use varies depending on the clinician, as the treatment is considered off label Ophthalmology has continued to use existing stock when required.
- **any plans or decisions to discontinue its use, and**
  - No formal plan to discontinue use, as use varies depending on the clinician, Intracinol would be the recommended licensed product for staining of the vitreous.
- **any identified or recommended alternative treatments.**
  - Intracinol licensed by MHRA as a device for staining vitreous.